Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BullFrog AI Holdings, Inc. is a biotechnology and artificial intelligence company focused on applying machine learning to biomedical and pharmaceutical data to improve drug development, clinical trial design, and precision medicine. The company operates at the intersection of biotechnology, artificial intelligence, and pharmaceutical research, offering computational tools designed to extract actionable insights from complex biological datasets. Its primary value proposition is enabling partners to better understand disease mechanisms, patient stratification, and treatment response using advanced analytics.
The company’s core offering centers on its proprietary bfLEAP™ platform, which applies causal AI and machine learning techniques to clinical, genomic, and real-world data. BullFrog AI primarily serves biopharmaceutical companies, academic research institutions, and life sciences organizations seeking to optimize R&D efficiency and reduce drug development risk. Founded in 2017, the company evolved from academic and government-supported research initiatives and became publicly listed in 2023, positioning itself as a niche provider of explainable AI solutions in life sciences.
Business Operations
BullFrog AI generates revenue primarily through data analytics services, licensing arrangements, and collaborative research agreements tied to the deployment of its bfLEAP™ platform. The platform is designed to integrate diverse datasets, including clinical trial data, biomedical research data, and real-world evidence, to support hypothesis generation and decision-making across the drug development lifecycle. Revenue is generally project-based and partner-driven, rather than derived from product sales at scale.
Operations are largely research- and technology-focused, with no reported commercial-stage therapeutics or internally developed drug candidates. The company conducts most of its activities within the United States and relies on a combination of in-house data science capabilities and external collaborations. BullFrog AI does not disclose large-scale manufacturing assets and appears to operate with a lean organizational structure, emphasizing intellectual property, software development, and scientific expertise.
Strategic Position & Investments
BullFrog AI’s strategic direction centers on expanding adoption of its bfLEAP™ platform through partnerships with pharmaceutical companies, biotechnology firms, and research organizations. Growth initiatives emphasize applying causal AI to areas such as oncology, rare diseases, and central nervous system disorders, where complex biology and heterogeneous patient populations create high unmet analytical needs.
The company has pursued a partnership-driven model rather than significant acquisitions, with public disclosures indicating limited or no material acquisitions to date. BullFrog AI positions itself within the emerging AI-enabled drug development sector, focusing on explainability and causal inference as differentiators relative to black-box AI approaches. Data inconclusive based on available public sources regarding material equity investments in other companies or extensive subsidiary holdings.
Geographic Footprint
BullFrog AI is headquartered in the United States, with its principal offices in Maryland. Its operational footprint is primarily domestic, reflecting its focus on U.S.-based pharmaceutical, biotechnology, and academic partners. The company’s workforce and research activities are concentrated in this region.
International exposure is largely indirect, arising from collaborations with global pharmaceutical companies and research institutions that operate across North America, Europe, and other regions. However, the company has not publicly disclosed significant foreign offices, subsidiaries, or standalone international operations as of its most recent filings.
Leadership & Governance
BullFrog AI is led by an executive team with experience in biotechnology, data science, and corporate leadership. The company’s governance structure reflects its status as a publicly traded emerging growth company, with a board overseeing strategic direction, capital allocation, and compliance.
Key executives include:
- Vin Singh – Founder and Chief Executive Officer
- Andrew Clarke – Chief Financial Officer
- Juan A. Bernal – Chief Technology Officer
- Peter E. Ascher – Chairman of the Board
Leadership has articulated a strategic vision centered on leveraging explainable AI to improve decision-making in life sciences and fostering long-term value through partnerships rather than asset-heavy development models.